Temporal Dynamics of Serum Perforin and Granzymes in Three Different Clinical Stages of Virus-Induced Severe Fever with Thrombocytopenia Syndrome.
Journal
The American journal of tropical medicine and hygiene
ISSN: 1476-1645
Titre abrégé: Am J Trop Med Hyg
Pays: United States
ID NLM: 0370507
Informations de publication
Date de publication:
06 09 2023
06 09 2023
Historique:
received:
05
05
2023
accepted:
04
06
2023
pmc-release:
01
09
2024
medline:
8
9
2023
pubmed:
1
8
2023
entrez:
31
7
2023
Statut:
epublish
Résumé
Virus-induced severe fever with thrombocytopenia syndrome (SFTS) induces a cell-mediated immune response that likely contributes to virus control in SFTS patients. To identify the temporal changes of the cell-mediated immune response, we investigated the changes in serum levels of perforin and granzymes at early periods after illness onset in SFTS patients. We analyzed 32 SFTS patients and compared the temporal patterns of serum perforin and granzyme A and B to that of 20 healthy control adults using the Mann-Whitney U test. Compared with healthy controls, the mean level of perforin was significantly reduced by 81% (P < 0.01) during the first week after illness onset, whereas granzyme B significantly increased by 4.6-fold (P = 0.02) in the first week after illness onset and decreased to normal afterward. During the study period, there was no significant difference in serum perforin and granzyme. These findings indicate that perforin and granzyme B in serum can be considered possible serologic markers that reflect the clinical stage of SFTS. Additional study is warranted for tracking circulating perforin and granzyme in different ages and for an extended period after illness onset.
Identifiants
pubmed: 37524330
doi: 10.4269/ajtmh.23-0269
pii: tpmd230269
pmc: PMC10484244
doi:
Substances chimiques
Granzymes
EC 3.4.21.-
Perforin
126465-35-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
554-558Références
J Infect Dis. 2014 Mar;209(6):816-27
pubmed: 24231186
J Exp Med. 1987 May 1;165(5):1371-82
pubmed: 3494808
Lancet Infect Dis. 2018 Oct;18(10):1127-1137
pubmed: 30054190
PLoS Pathog. 2021 Sep 16;17(9):e1009818
pubmed: 34529743
PLoS Negl Trop Dis. 2016 Dec 29;10(12):e0005264
pubmed: 28033338
Int J Infect Dis. 2018 May;70:72-80
pubmed: 29550447
N Engl J Med. 2011 Apr 21;364(16):1523-32
pubmed: 21410387
Pathog Dis. 2017 Sep 29;75(7):
pubmed: 28859400
Lancet Infect Dis. 2014 Aug;14(8):763-772
pubmed: 24837566
J Infect Dis. 2012 Oct 1;206(7):1095-102
pubmed: 22850122
Emerg Infect Dis. 2020 Apr;26(4):692-699
pubmed: 32186502
mBio. 2020 Sep 18;11(5):
pubmed: 32948688
Viruses. 2022 Nov 12;14(11):
pubmed: 36423119
Vaccine. 2015 Mar 3;33(10):1250-5
pubmed: 25645176
Clin Microbiol Infect. 2014 Nov;20(11):O870-8
pubmed: 24684627
Open Forum Infect Dis. 2023 Feb 18;10(4):ofad085
pubmed: 37035488
Crit Rev Immunol. 2014;34(5):359-88
pubmed: 25404045
Nat Rev Immunol. 2015 Jun;15(6):388-400
pubmed: 25998963
Front Cell Infect Microbiol. 2021 Mar 23;11:649570
pubmed: 33834006
Exp Mol Med. 2021 May;53(5):713-722
pubmed: 33953322
Clin Microbiol Infect. 2015 Jul;21(7):614-20
pubmed: 25769426
Emerg Infect Dis. 2018 Nov;24(11):2103-2105
pubmed: 30334706
Mol Immunol. 2010 Sep;47(15):2492-504
pubmed: 20580434